In part because of its resistance to many antibiotics, tuberculosis kills approximately 1.7 million people worldwide each year. But new research from the University of Notre Dame suggests that structures released by the infected cells may be used in tandem with antibiotics to boost the body’s immune system, helping fight off the disease.
The paper, published in EMBO Reports by Jeffrey Schorey, the George B. Craig Jr. Professor, and Yong Cheng, research assistant professor, both in the Department of Biological Sciences, describes how the structures, called extracellular vesicles (EVs), contain Mycobacterium tuberculosis RNA and transfer it to other cells. This starts a built-in weapon system against the disease in the form of an immune response.
Though extracellular vesicles containing RNA from viruses had been discovered years ago, Schorey and his collaborators recently discovered RNA from bacteria — Mycobacterium tuberculosis — in EVs. This discovery led to experiments described in the EMBO Reports paper to determine how the bacteria’s RNA was affecting the “target” cell, including cells infected by M. tuberculosis.
A key research discovery hinges on macrophages, which are cells of the immune system. These cells, when treated with EVs released from M. tuberculosis-infected cells, can control the infection better than macrophages not previously exposed to the EVs, Schorey and Cheng determined. “It had never before been shown that bacterial RNA in EVs can activate this sensing pathway, one that has primarily been thought to be involved in viral sensing,” Schorey said. The authors then show that EV-treated macrophages produce compounds like reactive oxygen species that can promote the killing of the M. tuberculosis once it infects the macrophage.
The discovery is important because it can lead to future therapies for treatment of tuberculosis. Preliminary data in the paper suggest that antibiotics might work better when combined with an immunotherapy based on using these EVs. The data from the mouse model showed that more of the bacterial-infected cells were killed with the combination of therapies than either antibiotics or EVs alone, Schorey noted.
The next steps for future research are to try this approach with other laboratory models, with the goal that they also show the benefit of combining EVs, as immunotherapy treatments, with antibiotics to treat drug-resistant tuberculosis.
Worldwide, more than 10 million people develop active tuberculosis each year. Furthermore, over two billion people are infected with the bacteria. This results in a reservoir of infected people who may develop disease if their immune systems are compromised.
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- We Have a Cure for the Deadliest Form of Tuberculosison August 16, 2019 at 12:17 pm
The Food and Drug Administration just approved the third and final part of a new drug regimen shown to cure the deadliest strain of tuberculosis. The regimen involves taking five pills every day ...
- Scientists Discover New Cure for the Deadliest Strain of Tuberculosison August 16, 2019 at 7:38 am
TSAKANE, South Africa — When she joined a trial of new tuberculosis drugs, the dying young woman weighed just 57 pounds. Stricken with a deadly strain of the disease, she was mortally terrified. Local ...
- A New Dose of Hope in the Battle With Tuberculosison August 16, 2019 at 7:36 am
Tuberculosis is the world’s deadliest infectious disease: Between 2007 and 2017, an estimated 94.5 million people caught tuberculosis, and more than 14 million died from it. Rising numbers are being ...
- Treatment for Extreme Drug-Resistant Tuberculosis Wins U.S. Government Approvalon August 16, 2019 at 6:49 am
The U.S. Food and Drug Administration has approved a drug regimen to treat an extreme form of multi-drug-resistant tuberculosis (TB). Nearly 90% of people infected with extensively drug-resistant (XDR ...
- How a new antibiotic destroys extremely drug-resistant tuberculosison August 16, 2019 at 6:25 am
The Food and Drug Administration on Wednesday approved a new antibiotic that, when combined with two existing antibiotics, can tackle the most formidable and deadly forms of tuberculosis.
- A new FDA-approved drug takes aim at a deadly form of tuberculosison August 16, 2019 at 3:24 am
An especially dangerous type of tuberculosis may have met its match. The U.S. Food and Drug Administration announced August 14 that it has approved the antibiotic pretomanid to help tackle what’s ...
- New treatment approved for drug-resistant tuberculosison August 15, 2019 at 11:18 am
(CNN)The US Food and Drug Administration approved a new treatment for highly drug-resistant tuberculosis, offering new hope in the fight against the world's most deadly infectious disease. TB most ...
- FDA approves drug for most deadly form of tuberculosison August 15, 2019 at 10:03 am
(HealthDay)—A new drug has been approved as part of a powerful, three-pronged treatment regimen for the most deadly strain of tuberculosis, the U.S. Food and Drug Administration announced Wednesday.
- FDA approves tuberculosis drug that works on hard-to-treat caseson August 14, 2019 at 2:00 pm
U.S. regulators have approved a new tuberculosis medication that shortens and improves treatment for the hardest-to-treat cases — a worsening problem in many poor countries. Decades of incomplete or ...
- After 20 years of research, RTI drug approved for drug-resistant tuberculosison August 14, 2019 at 12:53 pm
A new drug developed by RTI International scientists has been granted U.S. Food and Drug Administration (FDA) approval – offering hope to patients with drug resistant tuberculosis. The FDA's approval ...
via Bing News